Breast Cancer Clinical Trial
Official title:
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
| NCT number | NCT02969291 |
| Other study ID # | 776553-5 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | October 2016 |
| Est. completion date | October 2018 |
| Verified date | July 2019 |
| Source | Baystate Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
There is a well-documented association between physical activity & risk for breast cancer
development and recurrence. It is known that exercise interventions have been effective at
increasing physical activity levels in breast cancer survivors. Knowing that breast cancer
survivors are less active than non-cancer patients, a less active lifestyle places them at
risk of obesity and poor overall health, which in turn also increases risk of cancer and
cancer recurrence. Not all the reasons for the risk reduction are clear, however it is known
that hormones and other inflammatory markers play a role.
This study has three goals:
1. To investigate the feasibility of a home intervention designed to reduce sedentary
behavior.
2. Describe the effects of the intervention on levels of sedentary behavior, physical
activity, and symptoms.
3. Assess cost of the intervention.
| Status | Completed |
| Enrollment | 13 |
| Est. completion date | October 2018 |
| Est. primary completion date | October 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 20 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Stage I-III breast cancer survivors 20-80 who have completed primary treatment (surgery, radiation and/or chemotherapy) greater than 6 months but less than 5 years ago. Patients may be on adjuvant hormonal therapy - BMI > 25 (overweight or class I/II obese) - Not meeting current guidelines for regular exercise as defined by less than 150 minutes a week of moderate to vigorous physical activity - No gain or loss of >10% body weight over the prior 6 months. Exclusion Criteria: - Known diabetes - Known coronary artery disease - Pregnancy - Any injury that would limit mobility or require use of assisted mobility devices - Weight gain or loss of >10% body weight over the prior 6 months - Greater than 150 minutes a week of moderate to vigorous physical activity - Inability to provide informed consent - Non-english speaking |
| Country | Name | City | State |
|---|---|---|---|
| United States | Baystate Medical Center | Springfield | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Baystate Medical Center | University of Massachusetts, Amherst |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Sedentary Time | Change in minutes/day of sedentary time as recorded by ActivPal in all 25 participants pre and post intervention. | 8 weeks | |
| Secondary | Activity Level | Change in Activity level as recorded by Actigraph monitor in all 25 participants | 8 weeks | |
| Secondary | Glucose | Change in fasting glucose ( mmol/L)in all 25 participants | 8 weeks | |
| Secondary | Insulin | Change in insulin (pmol/L) in all 25 participants | 8 weeks | |
| Secondary | Total cholesterol | Change in total cholesterol (mmol) in all 25 participants | 8 weeks | |
| Secondary | High density lipoprotien cholesterol | Change in high density lipoprotein cholesterol (mmol) in all 25 participants | 8 weeks | |
| Secondary | Triglyceride | Change in triglycerides (mmol) in all 25 participants | 8 weeks | |
| Secondary | Body Mass Index | Change in Body Mass Index (kg/m2) in all 25 participants | 8 weeks | |
| Secondary | Waist Circumference | Change in waist circumference in cm in all 25 participants | 8 weeks | |
| Secondary | Systolic Blood pressure | Change in systolic blood pressure measured in mmHg in all 25 participants | 8 weeks | |
| Secondary | Diastolic Blood pressure | Change in diastolic blood pressure measured in mmHg in all 25 participants | 8 weeks | |
| Secondary | Cancer-related fatigue measured by change in PROMIS short form 8a in all 25 participants | 8 weeks | ||
| Secondary | Cancer-related fatigue as measured by change in Visual Analog scale in all 25 participants | 8 weeks | ||
| Secondary | Sedentary behavior self -efficacy | Change in Sedentary Behavior Self-Efficacy Scale (modified from BARSE) in all 25 participants | 8 weeks | |
| Secondary | Change in EORTC-QLQ-C30 scores in all 25 participants | 8 weeks | ||
| Secondary | Assessment of Intervention | Change in Assessment of Intervention questions on a scale of 1-5 in all 25 participants | 8 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |